• Explore /
  • Poster
  • / Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non–muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301.

Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non–muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301.

Abstract Poster

Authors

null

Dickon Hayne

UWA Medical School, University of Western Australia, Perth, Australia

Dickon Hayne , Martin R. Stockler , Andrew James Martin , Steve P McCombie , Danka Sinikovic Zebic , Patricia A. Bastick , Emma Kate Beardsley , Mark Frydenberg , William Green , Jeremy Grummet , Cynthia Hawks , Joseph Ischia , Andrew Mitterdorfer , Manish Patel , Matthew Roberts , Shomik Sengupta , Ratnesh Kumar Srivastav , Andrew David Redfern , Ian D. Davis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Other GU Kidney and Bladder Cancer

Clinical Trial Registration Number

NCT02948543

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4617)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4617

Abstract #

TPS4617

Poster Bd #

101a

Abstract Disclosures

Similar Posters

First Author: Elizabeth Chien Hern Liow

First Author: Zongren Wang

First Author: Neal D. Shore

First Author: Joseph M Jacob